CardioGrip IPH, Inc. – Trademark Portfolio
Entity Type: 03
CardioGrip IPH, Inc. holds 5 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 5 filings in this category. The portfolio also extends into Class 35 (Advertising & Business) across 4 Nice Classification classes. Currently, 4 trademarks are registered. Notable registered marks include ZONA, ZONARX, and ZONA PLUS. The owner is based in Boise, ID.
12554 W. Bridger Street, Suite 108
Boise, ID 83713
Showing of trademarks Trademarks
Trademark Classifications
CardioGrip IPH, Inc.'s trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Advertising; business management; business administration; office functions
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does CardioGrip IPH, Inc. have?
CardioGrip IPH, Inc. has 5 U.S. trademarks filed with the USPTO. Of these, 4 registered, 1 cancelled.
What trademark classes does CardioGrip IPH, Inc. file in?
CardioGrip IPH, Inc. files trademarks across 4 Nice Classification classes. The most active classes are Class 10 (Medical Apparatus), Class 35 (Advertising & Business), Class 9 (Computers & Electronics), Class 5 (Pharmaceuticals). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.
What are CardioGrip IPH, Inc.'s most well-known trademarks?
CardioGrip IPH, Inc.'s registered trademark portfolio includes well-known marks such as ZONA, ZONARX, and ZONA PLUS. These are among 4 currently registered trademarks in the portfolio.
What is CardioGrip IPH, Inc.'s trademark registration success rate?
CardioGrip IPH, Inc. has a 80% trademark registration rate, with 4 out of 5 resolved applications resulting in successful registration. Currently, 0 applications are pending review.